Ophthalmic compositions comprising combinations of a...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S023000, C514S913000

Reexamination Certificate

active

06248735

ABSTRACT:

SUMMARY OF THE INVENTION
This invention relates to novel ophthalmic compositions comprising a topical carbonic anhydrase inhibitor of structure:
wherein A, Z, R
1
and X are as hereinafter defined, or an ophthamologically acceptable salt thereof and a &bgr;-adrenergic antagonist selected from betaxolol, bufenolol, carteolol, levobunolol, metipranolol, and timolol, or an ophthalmologically acceptable salt thereof.
The invention is also concerned with the use of the novel ophthalmic compositions in the treatment of ocular hypertension.
More particularly, it relates to such ophthalmic combinations and their use in the treatment of ocular hypertension and glaucoma, wherein the &bgr;-adrenergic antagonist is 1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol, or an ophthalmologically acceptable salt thereof which name includes the (S)-(−)- and (R)-(+)-enantiomers and any mixtures thereof, including racemic material. The (S)-(−)-enantiomer is generally known as timolol.
BACKGROUND OF THE INVENTION
Glaucoma is a degenerative disease of the eye wherein the intraocular pressure is too high to permit normal eye function. As a result, damage may occur to the optic nerve head and result in irreversible loss of visual function. If untreated, glaucoma may eventually lead to blindness. Ocular hypertension, i.e., the condition of elevated intraocular pressure without optic nerve head damage or characteristic glaucomatous visual field defects, is now believed by the majority of ophthalmologists to represent merely the earliest phase in the onset of glaucoma.
Many of the drugs formerly used to treat glaucoma proved not entirely satisfactory. The early methods of treatment of glaucoma employing pilocarpine produced undesirable local effects that made this drug, though valuable, unsatisfactory as a first line drug. More recently, clinicians have noted that many &bgr;-adrenergic antagonists are effective in reducing intraocular pressure. While many of these agents are effective for this purpose, there exist some patients with whom this treatment is not effective or not sufficiently effective. Many of these agents also have other characteristics, e.g., membrane stabilizing activity, that become more apparent with increased doses and render them unacceptable for chronic ocular use.
The &bgr;-adrenergic antagonist (S)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol, timolol, was found to reduce intraocular pressure and to be devoid of many unwanted side effects associated with pilocarpine and, in addition, to possess advantages over many other &bgr;-adrenergic antagonists, e.g., to be devoid of local anesthetic properties, to have a long duration of activity, and to display minimal loss of effect with increased duration of dosing.
Although pilocarpine and &bgr;-adrenergic antagonists reduce intraocular pressure, none of these drugs manifests its action by inhibiting the enzyme carbonic anhydrase, and thus they do not take advantage of reducing the contribution to aqueous humor formation made by the carbonic anhydrase pathway.
Agents referred to as carbonic anhydrase inhibitors block or impede this inflow pathway by inhibiting the enzyme carbonic anhydrase. While such carbonic anhydrase inhibitors are now used to treat intraocular pressure by systemic routes, they thereby have the distinct disadvantage of inhibiting carbonic anhydrase throughout the entire body. Such a gross disruption of a basic enzyme system is justified only during an acute attack of alarmingly elevated intraocular pressure, or when no other agent is effective.
For several years, the desirability of directing the carbonic anhydrase inhibitor to only the desired ocular target tissue has been recognized. Because carbonic anhydrase inhibitors have a profound effect in altering basic physiological processes, the avoidance of a systemic route of administation serves to diminish, if not entirely eliminate, those side effects caused by inhibition of carbonic anhydrase such as metabolic acidosis, vomiting, numbness, tingling, general malaise and the like. Topically effective carbonic anhydrase inhibitors are disclosed in U.S. Pat. Nos. 4,386,098; 4,416,890; 4,426,388; 4,668,697; and 4,863,922 and PCT Publication WO 91/15486. As yet, no topically effective carbonic anhydrase inhibitors are generally available for clinical use.
Thus, when a carbonic anhydrase inhibitor is combined with a &bgr;-adrenergic antagonist, there is experienced an effect that reduces the intraocular pressure below that obtained by either medicament individually.
The activity of carbonic anhydrase inhibitors currently under development wanes 6 to 8 hours post-dose, meaning that as single agents these carbonic anhydrase inhibitors must be administered at least three times a day to maintain the desired lowering of intraocular pressure. The combination of this invention maintains the desired lowering of intraocular pressure for a full twelve hours. Because of this increased duration of action, the combination disclosed herein is effective when administered only twice a day. Patient compliance is anticipated to be greater with twice a day administration than with three times a day administration.
The use of oral carbonic anhydrase inhibitors in combination with the topical &bgr;-adrenergic antagonist timolol and the resulting multiplicity of their effects is disclosed in Berson et al.,
American Journal of Ophthalmology
1981, 92, 788-791. However, the combination of an oral carbonic anhydrase inhibitor with a topical &bgr;-adrenergic antagonist presents two disadvantages. The first disadvantage is that the systemic use of a carbonic anhydrase inhibitor inhibits carbonic anhydrase throughout the body and exerts the same profound negative effects on basic metabolism whether it is used alone or in combination with a topical &bgr;-adrenergic antagonist. Secondly, there is poor patient compliance with simultaneous administration of both an oral and topical medicament.
The combination disclosed herein is effective either by co-administration of the medicaments in one solution or as a combined therapy achieved by prior administration of either the carbonic anhydrase inhibitor or the &bgr;-adrenergic antagonist followed by administration of the other solution. The use of a single solution containing both active medicaments is preferred.
The combination of this invention is suggested in U.S. Pat. No. 4,863,922, but a precise formulation of the relative combination of medicaments to give effective reduction of intraocular pressure is neither taught nor disclosed therein.
There exists a patient population insufficiently responsive to available &bgr;-adrenergic antagonists who will benefit from the combination disclosed herein. Because of the combined effect of the &bgr;-adrenergic antagonist and the carbonic anhydrase inhibitor, these otherwise refractory patients can obtain a marked beneficial reduction in intraocular pressure from such a combination.
Furthermore, there exists a patient population who will benefit from a combination where the minimal dosage of one or both of the medicaments is employed, thus minimizing the possibility of the occurrence of undesirable effects of one or both of the medicaments which would be more likely to become apparent with chronic use at the higher dosage.
DETAILED DESCRIPTION OF THE INVENTION
The novel ophthalmic compositions of this invention comprise a therapeutically effective amount of a topical carbonic anhydrase inhibitor and a &bgr;-adrenergic antagonist. The topical carbonic anhydrase inhibitor of the novel composition has the structural formula:
or an ophthalmologically acceptable salt thereof wherein:
A is carbon or nitrogen, preferably carbon;
Z is —NHR or —OR;
R is C
1-6
alkyl, either straight or branched chain, preferably C
2-4
alkyl such as ethyl, propyl or isobutyl;
R
1
is
(a) hydrogen,
(b) C
1-3
alkyl, preferably methyl, ethyl or n-propyl, or
(c) C
1-4
alkoxy-C
1-4
alkyl, preferably methoxypropyl; and
X is —S(O)
2
— or —C(O)
2
—.
Th

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Ophthalmic compositions comprising combinations of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ophthalmic compositions comprising combinations of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic compositions comprising combinations of a... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2468227

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.